Document Detail


Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature.
MedLine Citation:
PMID:  22926198     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSIONS: 1. Rapid cessation of ERT results not only in the loss of the beneficial effects, but in a significant worsening of the patient's clinical status. 2. Decisions about the introduction of ERT, especially in patients severely affected, should be made carefully. 3. Once started, it is essential to keep an adequate administration schedule of ERT to maintain the clinical benefits of enzyme therapy.
Authors:
Agnieszka Jurecka; Zbigniew Żuberuber; Violetta Opoka-Winiarska; Grzegorz Węgrzyn; Anna Tylki-Szymańska
Related Documents :
16020888 - Thrombosed stanford type a dissection of the aorta in an elderly patient following a fall.
21180288 - Root canal complications: 'the hypochlorite accident'.
2310898 - On the nature of keloid and hypertrophic scars.
7404918 - Ureterocalycostomy for postpyelolithotomy stenosis after failure of intubated infundibu...
7847138 - Anomaly of venous system in congenital occipital dermal sinus.
19954528 - Abscess of adrenal gland caused by disseminated subacute nocardia farcinica pneumonia. ...
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2012-08-17
Journal Detail:
Title:  Molecular genetics and metabolism     Volume:  107     ISSN:  1096-7206     ISO Abbreviation:  Mol. Genet. Metab.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-29     Completed Date:  2013-03-27     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9805456     Medline TA:  Mol Genet Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  508-12     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Enzyme Replacement Therapy*
Humans
Iduronate Sulfatase / therapeutic use*
Mucopolysaccharidosis II / drug therapy*,  enzymology,  mortality,  pathology
Survival Analysis
Treatment Outcome
Withholding Treatment / ethics,  utilization*
Young Adult
Chemical
Reg. No./Substance:
EC 3.1.6.13/Iduronate Sulfatase; EC 3.1.6.13/idursulfase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tnf?, Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by bo...
Next Document:  Intrathecal chlorprothixene, cis(z)-flupenthixol, chlorpromazine and fluphenazine for prolonged spin...